221 related articles for article (PubMed ID: 23748853)
21. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.
Chen W; Cai F; Zhang B; Barekati Z; Zhong XY
Tumour Biol; 2013 Feb; 34(1):455-62. PubMed ID: 23238818
[TBL] [Abstract][Full Text] [Related]
22. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
24. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
25. Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer.
Yang X; Wang X; Shen H; Deng R; Xue K
Cell Biochem Biophys; 2015 Sep; 73(1):87-91. PubMed ID: 25669446
[TBL] [Abstract][Full Text] [Related]
26. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.
Debeb BG; Lacerda L; Anfossi S; Diagaradjane P; Chu K; Bambhroliya A; Huo L; Wei C; Larson RA; Wolfe AR; Xu W; Smith DL; Li L; Ivan C; Allen PK; Wu W; Calin GA; Krishnamurthy S; Zhang XH; Buchholz TA; Ueno NT; Reuben JM; Woodward WA
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075851
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
28. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients.
Toyama T; Kondo N; Endo Y; Sugiura H; Yoshimoto N; Iwasa M; Takahashi S; Fujii Y; Yamashita H
Jpn J Clin Oncol; 2012 Apr; 42(4):256-63. PubMed ID: 22323552
[TBL] [Abstract][Full Text] [Related]
29. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Roth C; Rack B; Müller V; Janni W; Pantel K; Schwarzenbach H
Breast Cancer Res; 2010; 12(6):R90. PubMed ID: 21047409
[TBL] [Abstract][Full Text] [Related]
30. Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.
Park IH; Kang JH; Lee KS; Nam S; Ro J; Kim JH
Tumour Biol; 2014 Dec; 35(12):12173-80. PubMed ID: 25179838
[TBL] [Abstract][Full Text] [Related]
31. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
32. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer.
Zhao FL; Hu GD; Wang XF; Zhang XH; Zhang YK; Yu ZS
J Int Med Res; 2012; 40(3):859-66. PubMed ID: 22906258
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women.
Orangi E; Motovali-Bashi M
Gene; 2019 Mar; 687():272-279. PubMed ID: 30468908
[TBL] [Abstract][Full Text] [Related]
34. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Expressed MicroRNAs as Prospective Biomarkers for Detection of Breast Cancer.
Mohamed AA; Allam AE; Aref AM; Mahmoud MO; Eldesoky NA; Fawazy N; Sakr Y; Sobeih ME; Albogami S; Fayad E; Althobaiti F; Jafri I; Alsharif G; El-Sayed M; Abdelgeliel AS; Abdel Aziz RS
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453838
[TBL] [Abstract][Full Text] [Related]
36. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
[TBL] [Abstract][Full Text] [Related]
37. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
39. Hematogenic Dissemination of Triple-negative Versus Hormonal Receptor-positive Breast Cancer Cells.
Carvalho MJ; Abrantes AM; Laranjo M; Paiva B; Torgal I; Cabrita AS; Botelho F; DE Oliveira CF
In Vivo; 2015; 29(4):435-44. PubMed ID: 26130788
[TBL] [Abstract][Full Text] [Related]
40. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
